In recent years, the success of endocrine therapies such as the aromatase inhibitors (AI) and selective estrogen receptor modulators (SERMs), has lowered the mortality rate of estrogen receptor-positive (ER+) breast cancer [4]. This evidence concerns the gene CYP19A1 and breast carcinoma.